Patient-tailored design for selective co-inhibition of leukemic cell subpopulations.
Ontology highlight
ABSTRACT: The extensive drug resistance requires rational approaches to design personalized combinatorial treatments that exploit patient-specific therapeutic vulnerabilities to selectively target disease-driving cell subpopulations. To solve the combinatorial explosion challenge, we implemented an effective machine learning approach that prioritizes patient-customized drug combinations with a desired synergy-efficacy-toxicity balance by combining single-cell RNA sequencing with ex vivo single-agent testing in scarce patient-derived primary cells. When applied to two diagnostic and two refractory acute myeloid leukemia (AML) patient cases, each with a different genetic background, we accurately predicted patient-specific combinations that not only resulted in synergistic cancer cell co-inhibition bu
SUBMITTER: Ianevski A
PROVIDER: S-EPMC7895436 | biostudies-literature | 2021 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA